Monte Rosa Therapeutics Q3 collaboration revenue jumps on Novartis milestone payment

Overview

• Biotechnology firm's Q3 collaboration revenue rose sharply, driven by Novartis milestone payments

• Company posted Q3 net profit, reversing a loss from prior year period

• Q3 operating expenses increased due to higher R&D and G&A costs

Outlook

• Monte Rosa expects cash resources to support operations into 2029

• Company plans to start Phase 2 MRT-8102 gout study in Q4 2026, data in H2 2027

• Phase 2b MRT-8102 study in coronary artery disease expected to begin in H1 2027

Result Drivers

• NOVARTIS MILESTONE - Q3 collaboration revenue rose mainly due to a $50 mln milestone from Novartis for starting Phase 2 study of MRT-6160 in Sjögren’s disease

• R&D SPENDING - Higher R&D expenses reflected increased investment in development and discovery programs

• INTEREST INCOME - Higher interest income contributed to net profit in the quarter

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Monte Rosa Therapeutics, Inc. is $27.00, about 149.5% above its November 4 closing price of $10.82

Reuters Recommended Reads

• Nov 4 - Nurix says Sanofi discontinues autoimmune disease drug program

• Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows

• Nov 4 - Vir Biotechnology Q3 net loss narrows on lower R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)